Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

76.50 -1.19 (-1.53%)
Streaming Delayed Price Updated: 9:51 AM EDT, Sep 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 623,803
Open 76.92
Bid (Size) 76.48 (6)
Ask (Size) 76.51 (8)
Prev. Close 77.69
Today's Range 76.38 - 76.97
52wk Range 61.24 - 82.41
Shares Outstanding N/A
Dividend Yield 1.35%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AIRSUPRA® (albuterol/budesonide) US prescribing information updated to reflect the statistically significant severe exacerbation risk reduction in patients with mild asthma compared with albuterol
From AstraZeneca
Via Business Wire
AstraZeneca's Fasenra Falls Short In Smoker's Lung Trial
AstraZeneca's Fasenra misses the primary COPD endpoint while Saphnelo's lupus trial shows significant improvements and consistent safety profiles. 
Via Benzinga

Performance

YTD
+16.1%
+16.1%
1 Month
-3.3%
-3.3%
3 Month
+8.1%
+8.1%
6 Month
+0.2%
+0.2%
1 Year
-2.6%
-2.6%

More News

Read More
Advancing Cancer Research Brings New Hope for Patients Worldwide
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
AstraZeneca Says Asthma Drug Failed Trial In Smoker’s Disease
Via Stocktwits
Retail Buzz Builds As AstraZeneca’s Tagrisso Combo Extends Lung Cancer Survival To Nearly 4 Years
Via Stocktwits
Advancing Cancer Research Brings New Hope for Patients Worldwide
Via FinancialNewsMedia
Topics Artificial Intelligence Intellectual Property
SAPHNELO self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis
From AstraZeneca
Via Business Wire
GSK Stock Climbs After-Hours On $30B US Investment Pledge As Trump Pressures Big Pharma To Build In America
Via Stocktwits
Topics Artificial Intelligence Government World Trade
AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit
Via Benzinga
Topics Government
The Weight of Progress: A New Era Dawns for Anti-Obesity Drugs, Reshaping Markets and Health
Via MarketMinute
Merck's Exit Highlights UK Risks Losing Pharma Investment Amid Rising Costs
Via Benzinga
China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order
Via Investor's Business Daily
Topics Government
FDA Expands Approval For AstraZeneca's Drug For Pediatric Patients With Rare Type Of Cancer
Via Benzinga
Trump's Biotech Playbook Ignites $350 Billion Investment Blitz
Via Benzinga
Topics ETFs Government
AstraZeneca Lung Cancer Combo Extends Patient Survival By Years In Key Study
Via Benzinga
Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again
Via Investor's Business Daily
These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts
Via The Motley Fool
TAGRISSO® (osimertinib) plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR-mutated advanced lung cancer
From AstraZeneca
Via Business Wire
AstraZeneca, Corning And More On CNBC's 'Final Trades'
Via Benzinga
Market Jitters: Wall Street Braces for Continued Volatility
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
AstraZeneca's Latest Drug Offers Hope For Millions Battling Hard-To-Control Blood Pressure
Via Benzinga
Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III ​trial
From AstraZeneca
Via Business Wire
AstraZeneca's $80 Billion Ambition Just Got A Big Infusion With New Hypertension Results
Via Investor's Business Daily
Looking Into AstraZeneca's Recent Short Interest
Via Benzinga
Get insights into the top gainers and losers of Tuesday's after-hours session.
Via Chartmill

Frequently Asked Questions

Is AstraZeneca PLC - American Depositary Shares publicly traded?
Yes, AstraZeneca PLC - American Depositary Shares is publicly traded.
What exchange does AstraZeneca PLC - American Depositary Shares trade on?
AstraZeneca PLC - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for AstraZeneca PLC - American Depositary Shares?
The ticker symbol for AstraZeneca PLC - American Depositary Shares is AZN on the Nasdaq Stock Market
What is the current price of AstraZeneca PLC - American Depositary Shares?
The current price of AstraZeneca PLC - American Depositary Shares is 76.50
When was AstraZeneca PLC - American Depositary Shares last traded?
The last trade of AstraZeneca PLC - American Depositary Shares was at 09/18/25 09:51 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.